Three-dimensional quantitative structure activity relationship approach series of 3-Bromo-4-(1-H-3-Indolyl)-2, 5-Dihydro-1H-2, 5- Pyrroledione as antibacterial agents
الموضوعات : Journal of the Iranian Chemical ResearchMukesh Chandra Sharma 1 , Smita Sharma 2 , Dharm Veer Kohli 3 , Subash Chandra Chaturvedi 4
1 - School of Pharmacy, Devi Ahilya Vishwavidyalaya, Khandwa Road, Indore (M.P)-452 001, India
2 - Department of Chemistry, Yadhunath Mahavidyalya Bhind (M.P)- 477001, India
3 - Department of Pharmaceutical Sciences, University Sagar (M.P) 470003, India
4 - Shri Arvindo, Institute of Pharmacy Ujjain, Road Indore (M.P) 453111, India
الکلمات المفتاحية: Staphylococcus aureus, Antibacterial, 2D QSAR,
ملخص المقالة :
The use of quantitative structure–activity relationships, since its advent, has becomeincreasingly helpful in understanding many aspects of biochemical interactions in drug research.This approach was utilized to explain the relationship of structure with biological activity ofantibacterial. For the development of new fungicides against, the quantitative structural–activityrelationship (QSAR) analyses for fungicidal activities of Pyrroledione Derivatives were carriedout using multiple linear regression (MLR) Quantitative structure–activity relationship (QSAR)analysis was performed on a series of 3-Bromo-4-(1-H-3-Indolyl)-2, 5-Dihydro-1H-2, 5-Pyrroledione Derivatives.QSAR investigations were based on Hansch's extra thermodynamicmulti-parameter approach. QSAR investigations reveal that steric and electrostatic interactionsare primarily responsible for enzyme–ligand interaction. These studies produced good predictivemodels and give statistically significant correlations of selective COX-2 inhibitory with physicalproperty, connectivity and conformation of molecule. Also when available COX-1 inhibitorydata was analyzed with descriptors obtained from chem. Office 2007, partial charge descriptor,van der Waal’s surface area and solvation energy gave statistically significant results. The resultsobtained by combining these methodologies give insights into the key features for designingmore potent analogs antibacterial.
[1] J.H. Block, J.M. Beale, Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical
Chemistry, Eleventh edition, 2004.
[2] Burgers Medicinal Chemistry and Drug Discovery, fifth edition, Wiley Inter Science, 1995.
[3] L. Laurence, J.S. Lazo, K. Lpanker, Goodman and Gilman’s The Pharmacological Basis of
Therapeutics” tenth edition, McGraw-Hill, 2006.
[4] David A. Williams, Thomas L. Lemke, Foye’s Principles of Medicinal Chemistry, fifth edition, 2002.
[5] H. Goker, C. Kus, D.W. Boykin, S. Yildiz, N. Altanlar, Bioorg. Med. Chem. 10 (2002) 2589–2596.
[6] M.J. Rybak, R.L. Akins, Drugs 61 (2001) 1–7.
[7] Y. He, B. Wu, J. Yang, D. Robinson, L. Risen, R. Ranken, L. Blyh, S. Sheng, E.E.Swayze, Bioorg.
Med. Chem. Lett. 13 (2003) 3253–3256.
[8] J.M. Fostel, P.A. Lartey, Drug Discov.Today 5 (2000) 25–32.
[9] A. Khalafi-Nezhad, M.N.S. Rad, H. Mohabatkar, Z. Asrari, B. Hemmateenejad, Bioorg. Med. Chem.
13 (2005) 1931–1938.
[10] S. Mahboobi, E. Eichhorn, M. Winkler, A. Sellemer, U. Mollmann, Euro. J. Med. Chem. 43 (2008)
633-656.
[11] P.Hanumantharao, S.Sambasivarao, L.K. Soni, A.K. Gupta, S.G. Kaskhedikar, Bioorg. Med. Chem.
Lett.15 (2005) 3167-3171.
[12] A.K. Gupta, A.M. Babu, S.G. Kaskhedikar, Indian J. Pharm. Sci. 66 (2004) 396-402.
[13] CS Chem Office, Version ultra 7.01, Cambridge Soft corp., 100 Cambridge Park, MA 02140-2317,
USA.
